Sign Up for a Free Account
  • Updated 03.13.2021
  • Released 02.07.2000
  • Expires For CME 03.13.2024



Historical note and terminology

Mitoxantrone was first approved in 1986 for the treatment of acute myelogenous leukemia. In 1996 it was approved to treat pain in patients with advanced hormone-refractory prostate cancer in combination with corticosteroids. In 1997, results of clinical trials were published, describing the potential of mitoxantrone in treating patients with progressive multiple sclerosis; it was approved by the Food and Drug Administration for this indication in 2000.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, 
including video clips of 
neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of 
neurology in 1,200 
comprehensive articles.

Questions or Comment?

MedLink, LLC

10393 San Diego Mission Rd, Suite 120

San Diego, CA 92108-2134

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660